Welcome to our dedicated page for Onconetix SEC filings (Ticker: ONCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Onconetix, Inc. (Nasdaq: ONCO) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures, offering a structured view of how this commercial-stage biotechnology company reports on its men’s health and oncology business. Onconetix’s filings span registration statements, current reports, and proxy materials, each providing different angles on its operations, capital structure, and governance.
Through registration statements on Form S‑1 and S‑1/A, Onconetix details equity financing arrangements such as PIPE transactions involving Series D and Series E convertible preferred stock and associated warrants, as well as an equity line of credit with Keystone Capital Partners. These documents describe the number of shares registered for resale, conversion and exercise prices, and the company’s status as a smaller reporting company and emerging growth company. They also explain the impact of the company’s 1‑for‑85 reverse stock split on share counts and per‑share data.
Current reports on Form 8‑K provide timely disclosure of material events, including PIPE financing closings, licensing agreements, promissory notes, Nasdaq listing notices, and strategic transactions. For example, 8‑K filings describe the terms of the Series D and Series E preferred stock and warrants, the licensing agreement between Proteomedix and Immunovia related to the PancreaSure pancreatic cancer test, and amendments and waivers associated with promissory notes tied to the ENTADFI asset acquisition.
The company’s definitive proxy statement on Schedule 14A outlines proposals for stockholder approval, such as director elections, ratification of the independent registered public accounting firm, and approvals required under Nasdaq rules for issuing common stock upon conversion of preferred stock and exercise of warrants. These materials also confirm the date and location of the annual meeting and summarize the board’s recommendations.
On Stock Titan, each new 10‑K, 10‑Q, 8‑K, S‑1, DEF 14A, or other filing is captured as it becomes available from EDGAR. AI-powered tools can be used to highlight key sections, such as risk factors, descriptions of Proclarix and ENTADFI, financing terms, and Nasdaq compliance disclosures. Users interested in insider activity can also review Form 4 filings, when available, to see reported transactions by directors and officers.
By using this page, investors and researchers can quickly locate Onconetix’s quarterly and annual reports, capital raising disclosures, and governance documents, and rely on AI summaries to interpret complex sections without reading every page of the underlying filings.